Polivy（polatuzumab vedotin-piiq）泊洛妥珠单抗

The MMAE conjugate Polivy (polatuzumab vedotin) is the first ADC drug approved to target CD79b. In June 2019, Polivy was approved by the US FDA in combination with BR therapy for the treatment of relapsed and refractory diffuse large B-cell lymphoma (R/R DLBCL) who have received at least 2 therapies; 2021 In March 2020, Polivy was approved by the Japanese Ministry of Health, Labor and Welfare (MHLW) to combine bendamustine and rituximab (BR therapy) for the treatment of relapsed or refractory (R/R) diffuse large B cell lymphoma (DLBCL).